Clinical Trials Directory

Trials / Unknown

UnknownNCT02528292

Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis

Phase 4 Study of Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Patients With Rheumatoid Arthritis Undergoing Treatment With Anti-TNF Therapy

Status
Unknown
Phase
Study type
Observational
Enrollment
24 (estimated)
Sponsor
Barts & The London NHS Trust · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will be an open label observational prospective study assessing the clinical efficacy of antiTNFα therapy and the alteration/impact on the synovial tissue, with specific regard to lymphoid aggregation, over a period of 12 months in patients with rheumatoid arthritis. Rheumatoid arthritis (RA) is one of the most important chronic inflammatory disorders in the UK. It affects approximately 1% of adults and causes considerable morbidity, substantially reduces quality of life and has a significant mortality. It results in large direct medical costs as well as extensive indirect social costs. Despite the significant therapeutic progress following the introduction of antiTNFα, a cure for RA is still elusive. At present the reasons for the variation in clinical response are not known. The main aim of this study is to test the hypothesis that there are distinct molecular and cellular phenotypes present within the synovial tissue that define specific disease subsets and provide characteristic prognostic implications. In particular, the aim is to assess the relationship between the presence of ectopic lymphoneogenesis (ELN) within the rheumatoid synovial membrane and response to antiTNFα therapy.

Conditions

Interventions

TypeNameDescription
PROCEDURESynovial biopsyUltrasound guided synovial biopsy of inflamed joint
DRUGAnti-TNF therapyTherapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab

Timeline

Start date
2010-10-01
Primary completion
2018-01-01
Completion
2018-04-01
First posted
2015-08-19
Last updated
2015-08-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02528292. Inclusion in this directory is not an endorsement.